SIGA$6.47
$6.37
Chart
Performance
Key Stats
AI SIGA Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuySIGA Technologies presents a compelling investment case driven by its critical role in health security and a strong antiviral product. While valuation metrics suggest it's reasonably priced, recent performance shows volatility. The company's financial health is robust, with significant cash reserves. Further monitoring of regulatory news and drug development progress is advised.
Thematic
SIGA Technologies is positioned within the critical health security and biopharmaceutical sector, with its primary product, TPOXX, addressing a significant unmet need for smallpox treatment. Government contracts and public health preparedness initiatives represent strong thematic tailwinds.
Fundamental
SIGA exhibits strong profitability with high net margins and excellent cash flow generation, supported by a very healthy balance sheet with substantial cash equivalents and minimal debt. The P/E ratio is moderate, suggesting reasonable valuation given its earnings.
Technical
The stock has shown recent positive momentum (5D, 1M, 6M, YTD performance), but the 1-year performance is negative. Technical indicators suggest mixed signals, with some oscillators indicating overbought conditions on shorter timeframes, while moving averages show a general bullish trend on longer timeframes.
| Factor | Score |
|---|---|
| Health Security & Biodefense | 90 |
| Antiviral Market Demand | 80 |
| Regulatory Approvals & Contracts | 70 |
| R&D and Pipeline Expansion | 60 |
| Competition | 65 |
| Factor | Score |
|---|---|
| Valuation | 75 |
| Profitability | 95 |
| Growth | 40 |
| Balance Sheet Health | 100 |
| Cash Flow | 90 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 65 |
| Volume Confirmation | 70 |
| Support & Resistance | 60 |
| Short-Term Indicators | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Attractive P/E Ratio
The Price-to-Earnings (P/E) ratio on a trailing twelve months (TTM) basis is 10.8, which is lower than the industry average, suggesting the stock may be undervalued relative to its earnings.
Strong Cash Position
The company has a substantial cash and cash equivalents balance of $155,400,262 as of Q4 2024, providing significant financial flexibility.
Bearish Points (7)
High Quarterly P/E Ratio
The most recent quarterly P/E ratio of -868.4 (Q1 2025) indicates potential unprofitability or an anomaly, while the Q4 2024 P/E of 8.5 is still higher than the TTM P/E, suggesting recent volatility.
Negative Long-Term Performance
The stock has experienced a significant decline of -22.77% over the past year, indicating strong headwinds or investor concerns impacting its value.
Calendar
April 2025
29
Ex-Dividend Date
May 2025
15
Next Dividend Date
August 2025
1
Next Earnings Date
H: $
A: $
L: $
Profile
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. Its lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Seasonals
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Major biodefense contractor and producer of anthrax and smallpox vaccines; a direct peer to SIGA in the government medical countermeasures market.
Weight: 90
Producer of Jynneos/Imvanex, the non-replicating smallpox/monkeypox vaccine; a direct competitor or complement for orthopoxvirus-related government contracts.
Weight: 85
A leading antiviral drug developer with a broad portfolio including HIV, hepatitis, and COVID-19's Remdesivir, showcasing extensive expertise in infectious diseases.
Weight: 80
A major pharmaceutical company with significant vaccine (e.g., Comirnaty) and antiviral (e.g., Paxlovid) development capabilities for infectious diseases.